PURPOSE: Abnormality of the brain norepinephrine transporter (NET) has been reported in several psychiatric and neuronal disorders. Since NET is an important target for the diagnosis of these diseases, the development of radiopharmaceuticals for imaging of brain NET has been eagerly awaited. In this study, we synthesized (S,S)-2-(alpha-(2-iodophenoxy)benzyl)morpholine [(S,S)-IPBM], a derivative of reboxetine iodinated at position 2 of the phenoxy ring, and evaluated its potential as a radiopharmaceutical for imaging brain NET using SPECT. METHODS: (S,S)-(123/125)I-IPBM was synthesized in a halogen exchange reaction. The affinity and selectivity of (S,S)-IPBM for NET was measured by assaying the displacement of (3)H-nisoxetine and (S,S)-(125)I-IPBM from the binding site in rat brain membrane, respectively. The biodistribution of (S,S)-(125)I-IPBM was also determined in rats. Furthermore, SPECT studies with (S,S)-(123)I-IPBM were carried out in the common marmoset. RESULTS: (S,S)-(125)I-IPBM was prepared with high radiochemical yields (65%) and high radiochemical purity (>98%). (S,S)-IPBM showed high affinity and selectivity for NET in the binding assay experiments. In biodistribution experiments, (S,S)-(125)I-IPBM showed rapid uptake in the brain, and the regional cerebral distribution was consistent with the density of NET. The administration of nisoxetine, a selective NET-binding agent, decreased the accumulation of (S,S)-(125)I-IPBM in the brain, but the administration of selective serotonin transporter and dopamine transporter binding agents caused no significant changes in the accumulation. Moreover, (S,S)-(123)I-IPBM allowed brain NET imaging in the common marmoset with SPECT. CONCLUSION: These results suggest that (S,S)-(123)I-IPBM is a potential SPECT radiopharmaceutical for imaging brain NET.
PURPOSE: Abnormality of the brain norepinephrine transporter (NET) has been reported in several psychiatric and neuronal disorders. Since NET is an important target for the diagnosis of these diseases, the development of radiopharmaceuticals for imaging of brain NET has been eagerly awaited. In this study, we synthesized (S,S)-2-(alpha-(2-iodophenoxy)benzyl)morpholine [(S,S)-IPBM], a derivative of reboxetine iodinated at position 2 of the phenoxy ring, and evaluated its potential as a radiopharmaceutical for imaging brain NET using SPECT. METHODS: (S,S)-(123/125)I-IPBM was synthesized in a halogen exchange reaction. The affinity and selectivity of (S,S)-IPBM for NET was measured by assaying the displacement of (3)H-nisoxetine and (S,S)-(125)I-IPBM from the binding site in rat brain membrane, respectively. The biodistribution of (S,S)-(125)I-IPBM was also determined in rats. Furthermore, SPECT studies with (S,S)-(123)I-IPBM were carried out in the common marmoset. RESULTS:(S,S)-(125)I-IPBM was prepared with high radiochemical yields (65%) and high radiochemical purity (>98%). (S,S)-IPBM showed high affinity and selectivity for NET in the binding assay experiments. In biodistribution experiments, (S,S)-(125)I-IPBM showed rapid uptake in the brain, and the regional cerebral distribution was consistent with the density of NET. The administration of nisoxetine, a selective NET-binding agent, decreased the accumulation of (S,S)-(125)I-IPBM in the brain, but the administration of selective serotonin transporter and dopamine transporter binding agents caused no significant changes in the accumulation. Moreover, (S,S)-(123)I-IPBM allowed brain NET imaging in the common marmoset with SPECT. CONCLUSION: These results suggest that (S,S)-(123)I-IPBM is a potential SPECT radiopharmaceutical for imaging brain NET.
Authors: M J Millan; A Gobert; F Lejeune; A Newman-Tancredi; J M Rivet; A Auclair; J L Peglion Journal: J Pharmacol Exp Ther Date: 2001-08 Impact factor: 4.030
Authors: Magnus Schou; Christer Halldin; Judit Sóvágó; Victor W Pike; Håkan Hall; Balázs Gulyás; P David Mozley; David Dobson; E Shchukin; Robert B Innis; Lars Farde Journal: Synapse Date: 2004-08 Impact factor: 2.562
Authors: S Chumpradit; M P Kung; C Panyachotipun; V Prapansiri; C Foulon; B P Brooks; S A Szabo; S Tejani-Butt; A Frazer; H F Kung Journal: J Med Chem Date: 1992-11-13 Impact factor: 7.446
Authors: Gilles D Tamagnan; Eric Brenner; David Alagille; Julie K Staley; Colin Haile; Andrei Koren; Michelle Early; Ronald M Baldwin; Frank I Tarazi; Ross J Baldessarini; Nachwa Jarkas; Mark M Goodman; John P Seibyl Journal: Bioorg Med Chem Lett Date: 2006-10-12 Impact factor: 2.823
Authors: M Ueda; Y Iida; A Tominaga; T Yoneyama; M Ogawa; Y Magata; H Nishimura; Y Kuge; H Saji Journal: Br J Pharmacol Date: 2010-02-05 Impact factor: 8.739
Authors: Balagopal Lakshmi; Mei-Ping Kung; Brian Lieberman; Jun Zhao; Rikki Waterhouse; Hank F Kung Journal: Nucl Med Biol Date: 2007-11-19 Impact factor: 2.408
Authors: Fanxing Zeng; Jiyoung Mun; Nachwa Jarkas; Jeffrey S Stehouwer; Ronald J Voll; Gilles D Tamagnan; Leonard Howell; John R Votaw; Clinton D Kilts; Charles B Nemeroff; Mark M Goodman Journal: J Med Chem Date: 2009-01-08 Impact factor: 7.446